BIONANO GENOMICS


Associated tags: Software, Spectrum, Patient, OGM, Biology, Genome, Medicine, SAN, Genomics, Doctor of Philosophy, Research

Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA

Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress

Retrieved on: 
Tuesday, May 9, 2023
HRD, Genomics, GAAP, Curie Institute (Paris), Doctor of Philosophy, Acquisition, Investment, Risk, DSM-IV codes, Bone marrow, University, NGS, Spectrum, Mosaic, Research, Whole genome sequencing, LRS, Children's Hospital Los Angeles, WGS, Growth, Hospital, OEM, OGM, NMPA, Trisomy, Total, BGPT, MRKH, DNA, Workflow, Cancer, SOC, Publication, Genetic disorder, Standard of care, University of Toronto, ASD, SAN, National Medical Products Administration, IVD, MD Anderson Cancer Center, Acceleration, Toronto, SVS, Sale, NVIDIA, Female, Breast cancer, Mobile phone, Video game, Medical device, Pharmaceutical industry, Dietary supplement, Renewable energy, Augusta University

GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.

Key Points: 
  • GAAP gross margin for the first quarter of 2023 was 28%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 non-GAAP¹ gross margin was 30%, compared to 15% from the first quarter of 2022.
  • First quarter 2023 GAAP operating expense was $39.9 million, compared to $30.8 million in the first quarter of 2022.
  • First quarter 2023 non-GAAP operating expense was $33.6 million, compared to $24.2 million in the first quarter of 2022.

Bionano to Report First Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 9, 2023

Retrieved on: 
Tuesday, May 2, 2023
SAN, Genomics, Mobile phone

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.

Key Points: 
  • SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2023 and to highlight recent corporate progress.

Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal

Retrieved on: 
Tuesday, May 2, 2023
Telephone, Internet, SAN, Proxy, Genomics, Holding company

The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023 , on June 14, 2023, at 10:00 a.m. Pacific Time.

Key Points: 
  • The annual meeting of stockholders will be held virtually, via live webcast at www.virtualshareholdermeeting.com/BNGO2023 , on June 14, 2023, at 10:00 a.m. Pacific Time.
  • Stockholders of record as of April 24, 2023, may vote at the annual meeting or by proxy over the telephone, through the internet or using the Notice of Internet Availability of Proxy Materials mailed to such stockholders.
  • Stockholders may change their vote at any time before the final vote at the annual meeting.
  • Details regarding voting procedures are included in the Company’s proxy statement for the annual meeting, filed with the U.S. Securities and Exchange Commission on April 28, 2023.

Bionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research

Retrieved on: 
Wednesday, April 26, 2023
CLL, Myelodysplastic syndrome, FISH, University, CDK6, TP53, Chronic lymphocytic leukemia, ALL, Acute lymphoblastic leukemia, Genomics, Bone marrow, SVS, KMT2A, Doctor of Philosophy, VAF, SV, Teaching hospital, Acute myeloid leukemia, Ruhr University Bochum, MDS, AML, Publication, SAN, In situ hybridization, Cytogenetics, OGM, University of Oulu, Vaccine, Microscope, TCL1A

The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.

Key Points: 
  • The authors concluded that OGM offers unbiased genome-wide analysis of structural variants (SVs) with high resolution.
  • The authors also noted OGM’s ability to detect currently unknown variants, which might give insight into disease biology and refine risk stratification.
  • evaluated the performance of OGM against traditional cytogenetic methods in 29 samples characterized as AML or ALL.
  • is one of the first studies to evaluate the utility of OGM in chronic lymphocytic leukemia (CLL) samples.

Bionano Announces Preliminary Q1 2023 Results and Business Updates

Retrieved on: 
Monday, April 24, 2023
CPT, Bank statement, Genomics, Doctor of Philosophy, Publication, SAN, Growth, PLA, OGM, III, Mobile phone, Video game, Pharmaceutical industry

Bionano has elected to withdraw its applications for Category I CPT codes for optical genome mapping (“OGM”).

Key Points: 
  • Bionano has elected to withdraw its applications for Category I CPT codes for optical genome mapping (“OGM”).
  • The first quarter 2023 would represent the 10th consecutive quarter of reporting quarter-over-quarter revenue growth dating back to the fourth quarter of 2020.
  • “At our inaugural Strategy Day in February 2023, we outlined our strategy and key anticipated milestones planned over the next two years.
  • Bionano is in the process of completing its customary quarter-end close and review procedures as of and for the quarter ended March 31, 2023, and the final results for this period could differ from the preliminary expected results disclosed in this press release.

Bionano Genomics Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Monday, April 17, 2023
News, Cryptocurrency

LOS ANGELES, April 17, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bionano Genomics, Inc. (“Bionano”) (NASDAQ: BNGO) investors that the firm has initiated an investigation into whether Bionano issued false and misleading statements to investors.

Key Points: 
  • LOS ANGELES, April 17, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bionano Genomics, Inc. (“Bionano”) (NASDAQ: BNGO) investors that the firm has initiated an investigation into whether Bionano issued false and misleading statements to investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • On or around April 17, 2023, Bionano issued and sold a Series A Preferred share with the equivalent of 3 million share voting power (the, “supervoting share”).
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Bionano Announces Presentation of OGM Utility Across Cancer Genomics Research Applications at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, April 13, 2023
AACR, Genomics, HRD, Cancer, American Association for Cancer Research, EST, Research, Medicine, MD Anderson Cancer Center, Biomarker, Curie Institute (Paris), SAN, Leukemia, OGM, Bone marrow, Pharmaceutical industry

AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.

Key Points: 
  • AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine.
  • The AACR conference will be held April 14-18, 2023, in Orlando, Florida.
  • As part of a sponsored session, three cancer genomics experts will share their latest research covering the utility of OGM in comprehensive genomic structural variation and homologous recombination deficiency (HRD) analysis of tumor biopsies.
  • The presenters will also discuss their use of OGM for the identification of cancer biomarkers that may be utilized in personal therapy approaches and for drug screening in leukemia research samples.

Bionano Announces Publication that Demonstrates OGM’s Utility for Resolving Complex Genetic Variation in Inherited Retinal Disease

Retrieved on: 
Thursday, April 6, 2023
IRD, Therapy, Genomics, Congenital hearing loss, NGS, Retinitis pigmentosa, SVS, Research, Paratriathlon, Retina, Doctor of Philosophy, Disorder, Radboud University Medical Center, Genetics, USH2A, SAN, OMIM, Genetic, Diagnosis, OGM, Usher, Gene, Pharmaceutical industry, Vaccine

Their results identified several pathogenic SVs had been overlooked in their initial genome analyses by NGS.

Key Points: 
  • Their results identified several pathogenic SVs had been overlooked in their initial genome analyses by NGS.
  • The publication illustrates the potential impact of combining NGS and OGM for more comprehensive variant analysis.
  • Genetic research in this area may help to improve the accuracy of diagnosis, prognostication, and treatment prospects of targeted therapeutics.
  • With new gene therapy and clinical trials related to IRD, research into the underlying genetic cause of IRDs is critical.

Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females

Retrieved on: 
Wednesday, March 22, 2023
Vagina, Pregnancy, FISH, CMA, Augusta University, Genomics, Parent, KT, SVS, Mosaic, Research, Doctor of Philosophy, Uterus, Disorder, SV, Karyotype, CNV, Chromosomal translocation, Patient, SNP, Fertility, OGM, Gene, Syndrome, PCR, Trisomy, Female, Disease, Pharmaceutical industry, Microscope, Birth control, Medical imaging, Vaccine, Agriculture, MRKH

MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.

Key Points: 
  • MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy.
  • Molecular diagnosis is helpful in determining the best treatment for MRKH, but because genetic causes are largely unknown, research into this prevalent class of disorders is key to enabling effective therapies.
  • In this study, researchers used OGM to analyze MRKH samples to detect a variety of SVs that may be relevant to MRKH’s genetic etiology in a single assay.
  • We believe the authors’ findings that indicate mosaicism, including for a trisomy 12, could be involved in the pathogenesis of MRKH were particularly significant,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis

Retrieved on: 
Wednesday, March 15, 2023
DSM-IV codes, Fragile X syndrome, LDT, Epilepsy, NIPS, SAN, CGG, ASD, Genome, Chromosome, Spectrum, Patient, SVS, History, OGM, Intellectual disability, Child, FMR1, Medical imaging

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV.

Key Points: 
  • SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV.
  • These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities.
  • The reports from this LDT will include a whole genome analysis to assess for SVs of diagnostic and prognostic value.
  • “We are pleased to see the launch of Bionano Laboratories' LDTs for postnatal and prenatal analysis, which can assist patients in their diagnostic and prognostic journey.